X生命科学计划在2025年将NASDAQ列入VERAXA生物技术名单,以扩大癌症药物开发。 Xlife Sciences plans NASDAQ listing for VERAXA Biotech in 2025 to expand cancer drug development.

XLife XScience AG计划在2025年将VERAXA生物技术AG列入NASDAQ,以加速其癌症治疗药物管道的增长。 Xlife Sciences AG plans to list VERAXA Biotech AG on NASDAQ in 2025, aiming to accelerate the growth of its cancer treatment drug pipeline. VERAXA生物技术公司总部设在瑞士,在德国开展业务,开发先进的抗体药物候选人和T细胞注射器。 VERAXA Biotech, headquartered in Switzerland with operations in Germany, develops advanced antibody drug candidates and T cell engagers. 该名单于12月13日获得董事会批准,预计将促进该公司在生物技术部门的扩张。 The listing, approved by the board on December 13, is expected to boost the company's expansion in the biotech sector.